Zobrazeno 1 - 10
of 16
pro vyhledávání: '"José M. Ponseti"'
Autor:
Manuel López-Cano, Ramon Vilallonga, Jamal Azem, Manuel Armengol, José M. Ponseti, Josep Gamez, Carmen Ruiz
Publikováno v:
European Journal of Cardio-Thoracic Surgery. 34:1062-1067
Objective We determined the effect of detecting ectopic thymic tissue in thymectomy specimens on the long-term outcome of patients with myasthenia gravis. Methods A total of 83 consecutive patients with generalized seropositive nonthymomatous myasthe
Autor:
Jamal Azem, Josep Gamez, Manuel Armengol, José M. Ponseti, Ramon Vilallonga, Manuel López-Cano
Publikováno v:
Annals of the New York Academy of Sciences. 1132:254-263
Tacrolimus is a macrolide T cell immunomodulator that is used in myasthenia gravis (MG) patients to affect muscle contraction (ryanodine receptor by modulating intracellular calcium-release channels and increasing muscular strength), glucocorticoid r
Autor:
Cecilia Garcia, N. Raguer, Sonia Cazorla, Laura Rooney Lorenzo, José M. Ponseti, Merce Canela, Gisela Gili, Josep Gamez, Maria Salvado
Publikováno v:
Journal of the neurological sciences. 360
Background Myasthenia gravis (MG) is an autoimmune disease caused by a failure of neuromuscular transmission. Familial clustering has been reported despite MG usually manifesting as a sporadic condition presumed not to be inherited. Our study investi
Autor:
Jamal Azem, Agustín Codina, Manuel Armengol, José M. Ponseti, J. Bruno Montoro, José Manuel Fort
Publikováno v:
Clinical Neurology and Neurosurgery. 107:187-190
Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1 mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between
Autor:
José M. Ponseti, Josep Gamez
Publikováno v:
Journal of Xiangya Medicine. 2:4-4
The recent publication of the first international, multicenter, prospective, singled-blinded, and randomized trial (MGTX trial) comparing extended transsternal thymectomy plus alternate-day prednisone with prednisone alone in generalized non-thymomat
Autor:
Norma Caritg, Ramon Vilallonga, José M. Ponseti, Josep Gamez, Manuel López-Cano, Manuel Armengol
Publikováno v:
Expert opinion on biological therapy. 9(1)
A single-centre, non-randomized, non-controlled study was designed to compare the long-term post-thymectomy clinical outcome in anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis (MG).A total
Autor:
José M, Ponseti, Josep, Gamez, Jamal, Azem, Manuel, López-Cano, Ramón, Vilallonga, Manuel, Armengol
Publikováno v:
Annals of the New York Academy of Sciences. 1132
Tacrolimus is a macrolide T cell immunomodulator that is used in myasthenia gravis (MG) patients to affect muscle contraction (ryanodine receptor by modulating intracellular calcium-release channels and increasing muscular strength), glucocorticoid r
Autor:
José M. Ponseti, José Manuel Fort, Manuel Armengol, Ramon Vilallonga, Jamal Azem, Josep Gamez, Manuel López-Cano, Martín Buera
Publikováno v:
Current medical research and opinion. 23(6)
Thymectomy is a standard treatment of myasthenia gravis (MG). Immunomodulating agents are frequently given during the post-thymectomy latency period until complete remission is fully consolidated.A single-centre, non-randomized, non-controlled study
Autor:
Ramon Vilallonga, Jamal Azem, Manuel López-Cano, José Manuel Fort, C. Cervera, M. Buera, José M. Ponseti, Manuel Armengol
Publikováno v:
Neurology. 64(9)
Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 +/- 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG scor
Autor:
Manuel Armengol-Carrasco, Jose Luis Sanchez-Garcia, Manuel López-Cano, José M Ponseti-Bosch, Eloi Espin-Basany
Publikováno v:
The Annals of thoracic surgery. 76(5)
Background Myasthenia gravis is by far the most common paraneoplastic syndrome of thymomas. There is little information regarding the influence of clinical variables and thymoma-associated factors on biologic development of myasthenia gravis. The aim